eMedicine Specialties > Vascular Surgery > Medical Topics
Peripheral Arterial Occlusive Disease: Follow-up
Updated: Oct 26, 2009
Follow-up
Further Outpatient Care
- Patients should be seen every 4-6 months to assess the effects of medical therapy. Review changes in walking distance, smoking habits, eating habits, and exercise performance.
- Control hypertension and diabetes if necessary. A repeat pulse examination and ABI complete the follow-up evaluation.
- Patients with worsening symptoms may require intervention and referral to a vascular surgeon.
Complications
- The most feared consequence is severe limb-threatening ischemia leading to amputation. However, studies of large patient groups with claudication reveal that amputation is uncommon.
- Boyd prospectively followed 1440 patients with intermittent claudication for as long as 10 years and reported that only 12.2% required amputation.
- In the Framingham study, only 1.6% of patients with claudication reached the amputation stage after 8.3 years of follow-up.
Prognosis
- Whether a patient progresses to limb amputation largely depends on the number and severity of cardiovascular risk factors (ie, smoking, hypertension, diabetes).
- Continued smoking has been identified as the most consistent adverse risk factor associated with the progression of the disease.
- Other factors are the severity of disease at the time of the initial patient encounter and, in some studies, the presence of diabetes.
- As with most patients with vascular disease, survival is less than that of age-matched control groups. Coronary artery disease, with a subsequent myocardial event, is the major contributor to outcome.
- Predicted mortality rates for patients with claudication at 5, 10, and 15 years of follow-up are approximately 30%, 50%, and 70%, respectively.
Patient Education
For excellent patient education resources, visit eMedicine's Circulatory Problems Center and Cholesterol Center. Also, see eMedicine's patient education articles Peripheral Vascular Disease, High Cholesterol, and Cholesterol FAQs.
Miscellaneous
Medicolegal Pitfalls
Misdiagnosis for intermittent claudication rarely leads directly to limb loss. However, make early referrals to a vascular surgeon to decrease the likelihood of any legal action.
More on Peripheral Arterial Occlusive Disease |
| Overview: Peripheral Arterial Occlusive Disease |
| Differential Diagnoses & Workup: Peripheral Arterial Occlusive Disease |
| Treatment & Medication: Peripheral Arterial Occlusive Disease |
Follow-up: Peripheral Arterial Occlusive Disease |
| Multimedia: Peripheral Arterial Occlusive Disease |
| References |
| « Previous Page | Next Page » |
References
Boyd AM. The natural course of arteriosclerosis of the lower extremities. Angiology. 1960;11:10.
[Best Evidence] Monaco M, Stassano P, Di Tommaso L, Pepino P, Giordano A, Pinna GB, et al. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. J Am Coll Cardiol. Sep 8 2009;54(11):989-96. [Medline].
O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. May 2009;49(5):1226-34. [Medline].
Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. Oct 2009;38(4):463-74. [Medline].
Samson RH. The role of statin drugs in the management of the peripheral vascular patient. Vasc Endovascular Surg. Aug-Sep 2008;42(4):352-66. [Medline].
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. Apr 2007;45(4):645-654; discussion 653-4. [Medline].
Cassar K, Bachoo P, Ford I, et al. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. Jul 2003;38(1):99-103. [Medline].
Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication: is a supervised exercise class worth while?. Br Med J. Jun 21 1980;280(6230):1503-5. [Medline].
Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med. Jun 23 2003;163(12):1469-74. [Medline].
Couch NP. On the arterial consequences of smoking. J Vasc Surg. May 1986;3(5):807-12. [Medline].
Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication. Current results of nonoperative management. Arch Surg. Apr 1984;119(4):430-6. [Medline].
Ekroth R, Dahllof AG, Gundevall B, et al. Physical training of patients with intermittent claudication: indications, methods, and results. Surgery. Nov 1978;84(5):640-3. [Medline].
Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg. Feb 1988;7(2):356-62. [Medline].
Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. May 27 1978;1(6124):1379-81. [Medline].
Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand. 1985;218(1):27-33. [Medline].
Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. Jan 1985;33(1):13-8. [Medline].
Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. May 1970;41(5):875-83. [Medline].
Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. Jul 1982;104(1):66-72. [Medline].
Reid DD, Brett GZ, Hamilton PJ, et al. Cardiorespiratory disease and diabetes among middle-aged male Civil Servants. A study of screening and intervention. Lancet. Mar 23 1974;1(7856):469-73. [Medline].
Rosenbloom MS, Flanigan DP, Schuler JJ, et al. Risk factors affecting the natural history of intermittent claudication. Arch Surg. Jul 1988;123(7):867-70. [Medline].
Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol. May 1992;45(5):529-42. [Medline].
Walsh DB, Gilbertson JJ, Zwolak RM, et al. The natural history of superficial femoral artery stenoses. J Vasc Surg. Sep 1991;14(3):299-304. [Medline].
Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg. Apr 2009;49(4):910-7. [Medline].
Further Reading
Keywords
peripheral arterial occlusive disease, PAOD, chronic arterial insufficiency, lower extremity claudication, lower extremity ischemia, lower-extremity claudication, lower-extremity ischemia, peripheral vascular disease, cholesterol, smoking, hypertension
Follow-up: Peripheral Arterial Occlusive Disease